Literature DB >> 20109616

Extending cord blood transplant to adults: dealing with problems and results overall.

Claudio G Brunstein1, Mary J Laughlin.   

Abstract

The development of newer strategies to overcome, in particular, the cell dose limitation, has increased the availability of umbilical cord blood (UCB) as a source of hematopoietic stem cells (HSC) for transplantation of adults. Among these strategies is the development of the double UCB, ex vivo, and reduced-intensity transplantation platforms. Several ongoing registry-based and single-institution and multicenter clinical trials are investigating ways to make UCB transplantation safer and to improve the outcomes of adults after UCB transplantation. We review the background data and promising newer strategies that will further expand the utilization of UCB for the treatment of adults. (c) 2010 Elsevier Inc. All rights reserved.

Mesh：

Year:  2010        PMID： 20109616     DOI： 10.1053/j.seminhematol.2009.10.010

Source DB:  PubMed          Journal:  Semin Hematol        ISSN： 0037-1963            Impact factor:   3.851


  8 in total

1.  Frequency and Risk Factors Associated with Cord Graft Failure after Transplant with Single-Unit Umbilical Cord Cells Supplemented by Haploidentical Cells with Reduced-Intensity Conditioning.

Authors:  Stephanie B Tsai; Hongtao Liu; Tsiporah Shore; Yun Fan; Michael Bishop; Melissa M Cushing; Usama Gergis; Lucy Godley; Justin Kline; Richard A Larson; Guadalupe Martinez; Sebastian Mayer; Olatoyosi Odenike; Wendy Stock; Amittha Wickrema; Koen van Besien; Andrew S Artz
Journal:  Biol Blood Marrow Transplant       Date:  2016-02-19       Impact factor: 5.742

Review 2.  Insights into the biology of cord blood stem/progenitor cells.

Authors:  H E Broxmeyer
Journal:  Cell Prolif       Date:  2011-04       Impact factor: 6.831

Review 3.  Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia.

Authors:  Melhem Solh
Journal:  World J Stem Cells       Date:  2014-09-26       Impact factor: 5.326

Review 4.  Strategies to prevent EBV reactivation and posttransplant lymphoproliferative disorders (PTLD) after allogeneic stem cell transplantation in high-risk patients.

Authors:  Nishitha Reddy; Katayoun Rezvani; A John Barrett; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2010-08-21       Impact factor: 5.742

5.  Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donors.

Authors:  N S Majhail; C G Brunstein; R Shanley; K Sandhu; B McClune; B Oran; E D Warlick; J E Wagner; D J Weisdorf
Journal:  Bone Marrow Transplant       Date:  2011-05-23       Impact factor: 5.483

6.  Higher Dose of Mycophenolate Mofetil Reduces Acute Graft-versus-Host Disease in Reduced-Intensity Conditioning Double Umbilical Cord Blood Transplantation.

Authors:  Nelli Bejanyan; John Rogosheske; Todd DeFor; Aleksandr Lazaryan; Kelli Esbaum; Shernan Holtan; Mukta Arora; Margaret L MacMillan; Daniel Weisdorf; Pamala Jacobson; John Wagner; Claudio G Brunstein
Journal:  Biol Blood Marrow Transplant       Date:  2015-02-03       Impact factor: 5.742

7.  Characteristics of chronic GVHD after cord blood transplantation.

Authors:  L F Newell; M E D Flowers; T A Gooley; F Milano; P A Carpenter; P J Martin; C Delaney
Journal:  Bone Marrow Transplant       Date:  2013-04-15       Impact factor: 5.483

8.  Alternative donors extend transplantation for patients with lymphoma who lack an HLA matched donor.

Authors:  V Bachanova; L J Burns; T Wang; J Carreras; R P Gale; P H Wiernik; K K Ballen; B Wirk; R Munker; D A Rizzieri; Y-B Chen; J Gibson; G Akpek; L J Costa; R T Kamble; M D Aljurf; J W Hsu; M S Cairo; H C Schouten; U Bacher; B N Savani; J R Wingard; H M Lazarus; G G Laport; S Montoto; D G Maloney; S M Smith; C Brunstein; W Saber
Journal:  Bone Marrow Transplant       Date:  2014-11-17       Impact factor: 5.483
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.